Protein biomarkers identify patients unlikely to benefit from primary prevention implantable cardioverter defibrillators: Findings from the prospective observational study of implantable cardioverter defibrillators (PROSE-ICD)

Alan Cheng, Yiyi Zhang, Elena Blasco-Colmenares, Darshan Dalal, Barbara Butcher, Sanaz Norgard, Zayd Eldadah, Kenneth A. Ellenbogen, Timm Dickfeld, David D. Spragg, Joseph E. Marine, Eliseo Guallar, Gordon F. Tomaselli

Research output: Contribution to journalArticlepeer-review

47 Scopus citations

Abstract

Background: Primary prevention implantable cardioverter defibrillators (ICDs) reduce all-cause mortality, but the benefits are heterogeneous. Current risk stratification based on left ventricular ejection fraction has limited discrimination power. We hypothesize that biomarkers for inflammation, neurohumoral activation, and cardiac injury can predict appropriate shocks and all-cause mortality in patients with primary prevention ICDs. Methods and Results: The Prospective Observational Study of Implantable Cardioverter Defibrillators (PROSe-ICD) enrolled 1189 patients with systolic heart failure who underwent ICD implantation for primary prevention of sudden cardiac death. The primary end point was an ICD shock for adjudicated ventricular tachyarrhythmia. The secondary end point was all-cause mortality. After a median follow-up of 4.0 years, 137 subjects experienced an appropriate ICD shock and 343 participants died (incidence rates of 3.2 and 5.8 per 100 person-years, respectively). In multivariableadjusted models, higher interleukin-6 levels increased the risk of appropriate ICD shocks. In contrast, C-reactive protein, interleukin-6, tumor necrosis factor-α receptor II, pro-brain natriuretic peptide (pro-BNP), and cardiac troponin T showed significant linear trends for increased risk of all-cause mortality across quartiles. A score combining these 5 biomarkers identified patients who were much more likely to die than to receive an appropriate shock from the ICD. Conclusions: An increase in serum biomarkers of inflammation, neurohumoral activation, and myocardial injury increased the risk for death but poorly predicted the likelihood of an ICD shock. These findings highlight the potential importance of serum-based biomarkers in identifying patients who are unlikely to benefit from primary prevention ICDs.

Original languageEnglish (US)
Pages (from-to)1084-1091
Number of pages8
JournalCirculation: Arrhythmia and Electrophysiology
Volume7
Issue number6
DOIs
StatePublished - Dec 1 2014
Externally publishedYes

Keywords

  • Arrhythmias, cardiac
  • Death, sudden, cardiac
  • Defibrillators, implantable
  • Inflammation
  • Prevention & control

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Fingerprint

Dive into the research topics of 'Protein biomarkers identify patients unlikely to benefit from primary prevention implantable cardioverter defibrillators: Findings from the prospective observational study of implantable cardioverter defibrillators (PROSE-ICD)'. Together they form a unique fingerprint.

Cite this